Precision BioSciences, iECURE Ink Licensing Pact For Gene Editing Therapies

  • Precision BioSciences Inc DTIL and iECURE announced a license and collaboration agreement.
  • Under the agreement iECURE plans to advance Precision's PBGENE-PCSK9 candidate into Phase 1 studies and gain access to Precision's PCSK9-directed ARCUS nuclease to develop additional gene-editing therapies for genetic diseases, initially targeting liver diseases.
  • iECURE plans to file a clinical trial application in 2022 to advance the PBGENE-PCSK9 through Phase 1 studies for familial hypercholesterolemia (FH). 
  • Precision will retain rights to PBGENE-PCSK9.
  • In return, Precision has granted iECURE a license to use its PCSK9-directed ARCUS nuclease to insert genes into the well-characterized PCSK9 locus to develop treatments for four other pre-specified rare genetic diseases. 
  • Precision will receive an equity stake in iECURE and is eligible to receive milestone and royalty payments.
  • Read Next: Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications.
  • Price Action: DTIL stock is up 5.54% at $13.33 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefsLiver DiseasePhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!